Floatz logo

Epacadostat

Urothelial Carcinoma

Explore 163 assets in Urothelial Carcinoma →
Floatz Rating
BB65/100
Confidence
Indicative
v0.2
Sponsor
Incyte Corporation
Modality
Small molecule
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT03374488CT.gov
Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma
—Completed———
NCT03361865CT.gov
Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)
—Completed———
NCT02298153CT.gov
A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma
—Terminated———
NCT02318277CT.gov
A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)
—Completed———
NCT02178722CT.gov
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
—Completed———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Urothelial Carcinoma

AssetSponsorPhaseRating
Epacadostat (this asset)Incyte CorporationP3BB · 65
CyclophosphamideBeijing BiotechP3BB
DurvalumabAlliance for Clinical Trials in OncologyP3BB
Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)Vasgene Therapeutics, IncP2/3BB
Cis-Diamminedichloroplatinum IiNagoya UniversityP3BB
PembrolizumabSutro Biopharma, Inc.P3BB
Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor Receptor Type Vegfr-2 Extracellular Domain) (Human Monoclonal Imc-1121B .Gamma.-Chain), Disulphide With Human Monoclonal Imc-1121B .Kappa.-Chain, DimerEli Lilly and CompanyP3BB
DocetaxelNuCana plcP3BB
RetifanlimabIncyte CorporationP2BB

+42 more in the Urothelial Carcinoma cohort

Other indications for Epacadostat

IndicationSponsorPhaseRating
Ovarian Carcinoma—P2B · 59
Renal Cell Carcinoma—P3B · 56
Head And Neck Cancer—P3CCC · 54

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Epacadostat in Urothelial Carcinoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/epacadostat-urothelial-carcinoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →